March 15, 2013—The Senate yesterday defeated an amendment to a government-wide fiscal 2013 spending bill that included language to establish a 340B drug discount program user fee. Sen. Tom Harkin's (D-Iowa) amendment to the Continuing Appropriations Act (H.R. 933), which needed 60 votes to pass, failed by a vote 54 to 45. … [Read more...]
HRSA Drafting All-Inclusive Regulation for 340B
Comprehensive rule would be for entire program, Pedley saysMarch 14, 2013—The Health Resources and Services Administration (HRSA) is developing a comprehensive regulation for the entire 340B drug discount program that, among other provisions, would restate which patients may receive 340B-discounted medicines. Office of Pharmacy Affairs (OPA) Director Cmdr. Krista Pedley disclosed the plan for an omnibus 340B rule during a March 12 … [Read more...]
HRSA Issues Policy Release on 340B Hospital Eligibility
Elaborates on criteria for hospitals not owned or operated by governmentMarch 13, 2013—The Health Resources and Services Administration (HRSA) has added additional detail to its policy on the criteria that hospitals that are not publicly owned or operated must meet to be eligible for 340B drug discounts. In its September 2011 report on 340B, the Government Accountability Office called on HRSA to further specify 340B eligibility criteria for such … [Read more...]
“Significant Changes” Coming to 340B Contract Pharmacy Registration
OPA holding webinar for covered entities on March 20March 12, 2013—The Office of Pharmacy Affairs (OPA) is making "significant changes" to the way that health care providers register contract pharmacies in the 340B drug discount program, the office says in an email that providers began receiving late last week. According to the notification, the changes, which were not described in the email, take effect with the next … [Read more...]
HRSA and OPA Brace for Automatic Spending Cuts
Sequestration's possible effect on 340B program still isn't knownMarch 5, 2013—The Health Resources and Services Administration (HRSA) will have its funding reduced by $605 million for the seven months remaining in fiscal 2013 after Congress and the White House failed to prevent government-wide automatic cuts from taking effect. The effects on the 340B drug discount program, if any, are not yet clear. … [Read more...]
340B Recertification Deadline Extended to March 15
Extra time granted to health and hemophilia centers and five other entity typesMarch 5, 2013—The Office of Pharmacy Affairs (OPA) has extended the 340B recertification deadline for community health centers, hemophilia treatment centers, and five other types of covered entities to March 15. OPA announced the extension on its 340B covered entity database homepage today. … [Read more...]
Two New FAQs on 340B Group Purchasing Prohibition
OPA and Apexus both issue guidance addressing 340B drugs in mixed-use settingsMarch 1, 2013—The Office of Pharmacy Affairs (OPA) and Apexus/340B Prime Vendor Program (PVP) have each issued lengthy FAQs fleshing out OPA's new interpretation of the 340B statute's "GPO prohibition." The 340B law prohibits disproportionate share (DSH), children's, and free-standing cancer hospitals from participating in group purchasing organizations for 340B drugs, which … [Read more...]